PTIX
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 1.14 | $0 | -$410,427 |
| 2025 Q3 | -0.47 | $0 | -$1M |
| 2025 Q2 | -1.37 | $0 | -$1M |
| 2025 Q1 | -2.75 | $0 | -$1M |
| 2024 Q4 | -0.24 | -$25,143 | -$819,791 |
| 2024 Q3 | -0.14 | $0 | -$185,661 |
| 2024 Q2 | -0.36 | $0 | -$2M |
| 2024 Q1 | -0.39 | $0 | -$2M |